A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia

Journal of Psychiatric Research

Volumn 30, Issue 6, 1996, Pages 441-451

  Benkert, Otto ^a   Gründer, Gerhard ^a   Wetzel, Hermann ^a   Hackett, David ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Wyeth Ayerst Clin Res and D   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMIPRAMINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPOTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MELANCHOLIA; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREMOR; VERTIGO; XEROSTOMIA;

EID: 0030293903     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(96)00029-5     Document Type: Article

References (27)

1. Altamura, A. C., Montgomery, S. A., & Wernicke, J. F. (1988). The evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression. British Journal of Psychiatry, 153(3), 109-112.
2. Beasley, C. M. Jr, Bosomworth, J. C., & Wernicke, J. F. (1990). Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacology Bulletin, 26, 18-24.
3. Clerc, G. E., Ruimy, P., Verdeau-Paillès, J. (1994). A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. International Clinical Psychopharmacology, 9, 138-143.
4. Cunningham, L. A., Borison, R. L., Carman, J. S., Choniard, G., Crowder, J. E., Diamond, B. I., Fischer, D. E., & Hearst, E. (1994), A comparison of venlafaxine, trazodone, and placebo in major depression. Journal of Clinical Psychopharmacology, 14, 99-106.
5. Derivan, A., Entsuah, A. R., & Kikta, D. (1995). Venlafaxine: measuring the onset of antidepressant action. Psychopharmacology Bulletin, 31, 437-445.
6. Dierick, M., Ravizza, L., Realini, R., & Martin, A. (1996). A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 20, 57-71.
7. Dunner, D. L., & Dunbar, G. C. (1992). Optimal dose regimen for paroxetine. Journal of Clinical Psychiatry, 53(suppl), 21-26.
8. Gram, L. F. (1994) Fluoxetine. New England Journal of Medicine, 331, 1354-1361.
9. Gründer, G., Wetzel, H., Schlößer, R., & Benkert, O. (1996). Subchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure and heart rate: assessment by automatic 24 hour monitoring. Pharmacopsychiatry, 29, 72-78.
10. Guelfi, J. D., White, C., Hackett, D., Guichoux, J. Y., & Magni, G. (1995). Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. Journal of Clinical Psychiatry, 59, 450-458.
11. Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No. (ADM)76-338, Rockville, MD: National Institutes of Mental Health.
12. Hamilton, M. A. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry, 23, 56-62.
13. Huitfeldt, B., & Montgomery, S. (1983). Comparison between zimelidine and amitriptyline of efficacy and adverse symptoms. Acta Psychiatrica Scandinavia, 308(suppl 68), 55-70.
14. Klerman, G. L., Weissman, M. M., Frank, E., Kocsis, J. H., Markowitz, J. C., Montgomery, S. (1994). Evaluating drug treatments of depressive disorders. In R. F. Prien and D. S. Robinson (Eds). Clinical Evaluation of Psychotropic Drugs (pp. 281-325). New York: Raven Press.
15. Mendels, J., Johnston, R., Mattes, J., & Riesenberg, R. (1993). Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacology Bulletin, 29, 169-174.
16. Michels, R., & Marzuk, P. M. (1993). Progress in psychiatry (Second of two parts). New England Journal of Medicine, 329, 628-638.
17. Montgomery, S. A., & Asberg, M. (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382-389.
18. Muth, E. A., Moyer, J. A., Haskins, J. T., Andree, T. H., Husbands, G. E. M. (1991). Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Development Research, 23, 191-199.
19. Nierenberg, A. A., Feighner, J. P., Rudolph, R., Cole. J. O., & Sullivan, J. (1994). Venlafaxine for treatment-resistant unipolar depression. Journal of Clinical Psychopharmacology, 14, 419-423.
20. Potter, W. Z., Rudorfer, M. V., & Manji, H. (1991). The pharmacologic treatment of depression. New England Journal of Medicine, 325, 633-642.
21. Preskorn, S. H., & Lane, R. (1995). Sertraline 50 mg: the optimal daily dose in treating depression. International Clinical Psychopharmacology, 10, 129-141.
22. Regier, D. A., Boyd, J. H., & Burke, J. D. (1988). One-month prevalence of mental disorders in the United States: based on five epidemiological catchment area sites. Archives of General Psychiatry, 45, 977-986.
23. Rudolph, R., Entsuah, R., & Derivan, A. (1991). Early clinical response in depression to venlafaxine hydrochloride (abstract). Biological Psychiatry, 29, 630S.
24. Schweizer, E., Feighner, J., Mandos, L., & Rickels, K. (1994). Comparison of venlafaxine and imipramme in the acute treatment of major depression in outpatients. Journal of Clinical Psychiatry, 55, 104-108.
25. Shrivastava, R., Cohn, C., Crowder, J., Davidson, J., Dunner, D., Feighner, J., Kiev, A., & Patrick, R. (1994). Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. Journal of Clinical Psychopharmacology, 14, 322-329.
26. Stassen, H. H., Angst, J., & Delini-Stula, A. (1994). Severity at baseline and onset of improvement in depression. Meta-analysis of imipramine and moclobemide versus placebo. European Psychiatry, 9, 129-136.
27. Stassen, H. H., Delini-Stula, A., & Angst, J. (1993). Time course of improvement under antidepressant treatment: a survival-analytical approach. European Neuropsychopharmacology, 3, 127-135.